106 related articles for article (PubMed ID: 18928597)
21. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
22. [Involvement of AKT/eNOS in brain derived neurotrophic factor-induced angiogenesis].
Wang YD; Hu Y; Sun CY; He WJ; Zhang XP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):529-33. PubMed ID: 17172126
[TBL] [Abstract][Full Text] [Related]
23. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
24. Brain-derived neurotrophic factor promotes growth and migration of multiple myeloma cells.
Hu Y; Sun CY; Wang HF; Guo T; Wei WN; Wang YD; He WJ; Wu T; Tan H; Wu TC
Cancer Genet Cytogenet; 2006 Aug; 169(1):12-20. PubMed ID: 16875931
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.
Ozaki S; Kosaka M; Wakatsuki S; Abe M; Koishihara Y; Matsumoto T
Blood; 1997 Oct; 90(8):3179-86. PubMed ID: 9376601
[TBL] [Abstract][Full Text] [Related]
26. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
27. Enhancing the anti-multiple myeloma efficiency in a cancer stem cell xenograft model by conjugating the ABCG2 antibody with microbubbles for a targeted delivery of ultrasound mediated epirubicin.
Shi F; Li M; Wu S; Yang F; Di W; Pan M; Zhao F; Luo S; Gu N; Dou J
Biochem Pharmacol; 2017 May; 132():18-28. PubMed ID: 28232025
[TBL] [Abstract][Full Text] [Related]
28. [Role of multiple myeloma cells on normal endothelial cells in co-culture system].
Wang YD; Hu Y; Sun CY; Wang HF
Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):658-61. PubMed ID: 19176056
[TBL] [Abstract][Full Text] [Related]
29. Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma.
Guo D; Li C; Teng Q; Sun Z; Li Y; Zhang C
Neoplasma; 2013; 60(1):33-40. PubMed ID: 23067214
[TBL] [Abstract][Full Text] [Related]
30. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
[TBL] [Abstract][Full Text] [Related]
31. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
La Rocca F; Airoldi I; Di Carlo E; Marotta P; Falco G; Simeon V; Laurenzana I; Trino S; De Luca L; Todoerti K; Villani O; Lackmann M; D'Auria F; Frassoni F; Neri A; Del Vecchio L; Musto P; Cilloni D; Caivano A
Cell Oncol (Dordr); 2017 Oct; 40(5):483-496. PubMed ID: 28721629
[TBL] [Abstract][Full Text] [Related]
32. N-Propionyl polysialic acid precursor enhances the susceptibility of multiple myeloma to antitumor effect of anti-NprPSA monoclonal antibody.
Xiong H; Liang AB; Xiu B; Fu JF; Ding Y; Chen YH
Acta Pharmacol Sin; 2012 Dec; 33(12):1557-62. PubMed ID: 23123647
[TBL] [Abstract][Full Text] [Related]
33. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
[TBL] [Abstract][Full Text] [Related]
34. Brain-derived neurotrophic factor increases vascular endothelial growth factor expression and enhances angiogenesis in human chondrosarcoma cells.
Lin CY; Hung SY; Chen HT; Tsou HK; Fong YC; Wang SW; Tang CH
Biochem Pharmacol; 2014 Oct; 91(4):522-33. PubMed ID: 25150213
[TBL] [Abstract][Full Text] [Related]
35. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
36. PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells.
Li M; Shi F; Fei X; Wu S; Wu D; Pan M; Luo S; Gu N; Dou J
Exp Biol Med (Maywood); 2017 May; 242(9):996-1004. PubMed ID: 28056549
[TBL] [Abstract][Full Text] [Related]
37. Antitumor efficacy of lidamycin against human multiple myeloma RPMI 8226 cells and the xenograft in nonobese diabetic/severe combined immunodeficiency mice.
Zhen Y; Shang B; Liu X; Lin Y; Zhen Y
J Cancer Res Ther; 2016; 12(1):182-7. PubMed ID: 27072234
[TBL] [Abstract][Full Text] [Related]
38. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
[TBL] [Abstract][Full Text] [Related]
39. Brain-derived neurotrophic factor promotes tumorigenesis via induction of neovascularization: implication in hepatocellular carcinoma.
Lam CT; Yang ZF; Lau CK; Tam KH; Fan ST; Poon RT
Clin Cancer Res; 2011 May; 17(10):3123-33. PubMed ID: 21421859
[TBL] [Abstract][Full Text] [Related]
40. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H; Hideshima T; Fulciniti M; Lutz RJ; Yasui H; Okawa Y; Kiziltepe T; Vallet S; Pozzi S; Santo L; Perrone G; Tai YT; Cirstea D; Raje NS; Uherek C; Dälken B; Aigner S; Osterroth F; Munshi N; Richardson P; Anderson KC
Clin Cancer Res; 2009 Jun; 15(12):4028-37. PubMed ID: 19509164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
